The pro-survival MCL1 protein is overexpressed in many cancers, including B-cell non-Hodgkin lymphomas (B-NHL). S63845 is a highly specific inhibitor of MCL1. We analyzed mechanisms of sensitivity/resistance to S63845 in preclinical models of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. Annexin V-based cytotoxic assays, Western blot analysis, protein co-immunoprecipitation, and cell clones with manipulated expression of BCL2 family proteins were used to analyze mechanisms of sensitivity to S63845. Experimental in vivo therapy with S63845 and/or venetoclax was performed using patient-derived xenografts (PDX) of treatment-refractory B-NHL. A subset of DLBCL and majority of Burkitt lymphoma cell lines were sensitive to S63845. The level of BCL2 protein expression was the major determinant of resistance to S63845: BCL2 serves as a buffer for pro-apoptotic proteins released from MCL1 upon exposure to S63845. While BCL2-negative lymphomas were effectively eliminated by single-agent S63845, its combination with venetoclax was synthetically lethal in BCL2-positive PDX models. Concerning MCL1, both, the level of MCL1 protein expression, and its occupational status represent key factors mediating sensitivity to S63845. In contrast to MCL1-BIM/BAK1 complexes that prime lymphoma cells for S63845-mediated apoptosis, MCL1-NOXA complexes are associated with S63845 resistance. In conclusion, MCL1 represents a critical survival molecule for most Burkitt lymphomas and a subset of BCL2-negative DLBCLs. The level of BCL2 and MCL1 expression and occupational status of MCL1 belong to the key modulators of sensitivity/resistance to S63845. Co-treatment with venetoclax can overcome BCL2-mediated resistance to S63845, and enhance efficacy of MCL1 inhibitors in BCL2-positive aggressive B-NHL.

1st Department of Medicine Department of Hematology Charles University General Hospital Prague Czech Republic

BIOCEV 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Biotechnology CAS BIOCEV Vestec Czech Republic

Institute of Epigenetics and Stem cells Helmholtz Centre Munich Germany

Institute of Molecular Genetics CAS Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Pathology Charles University General Hospital Prague Czech Republic

Prague University of Economics and Business Prague Czech Republic

Zobrazit více v PubMed

Klanova M, Klener P. BCL-2 proteins in pathogenesis and therapy of B-cell non-hodgkin lymphomas. Cancers 2020;12:938. PubMed PMC

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42. PubMed

Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 2013;121:4861–6. PubMed PMC

Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 2018;34:879–91. PubMed

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. . Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225–36. PubMed

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. . Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018;19:216–28. PubMed

Wei AH, Strickland SA, Jr., Hou JZ, Fiedler W, Lin TL, Walter RB, et al. . Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol 2019;37:1277–84. PubMed PMC

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. . Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol 2017;35:826–33. PubMed PMC

Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. . Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood 2019;133:1964–76. PubMed PMC

Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, et al. . Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica 2020;105:2298–307. PubMed PMC

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–47. PubMed

Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. . BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012;26:1383–90. PubMed

Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. . BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961–8. PubMed

Masque-Soler N, Szczepanowski M, Kohler CW, Aukema SM, Nagel I, Richter J, et al. . Clinical and pathological features of Burkitt lymphoma showing expression of BCL2–an analysis including gene expression in formalin-fixed paraffin-embedded tissue. Br J Haematol 2015;171:501–8. PubMed

Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD, et al. . MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001;97:3902–9. PubMed

Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, et al. . MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004;35:1095–100. PubMed

Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, et al. . MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 2013;27:1381–90. PubMed

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. . The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016;538:477–82. PubMed

Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. . Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res 2015;22:1138–49. PubMed

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, et al. . Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res 2019;25:4455–65. PubMed

Bonifacino JS, Gershlick DC, Dell'Angelica EC. Immunoprecipitation. Curr Protoc Cell Biol 2016;71:7.2.1–7.2.24. doi: 10.1002/cpcb.3. PubMed

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. . DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013;31:827–32. PubMed PMC

Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, et al. . Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 2014;32:1262–7. PubMed PMC

Smith VM, Dietz A, Henz K, Bruecher D, Jackson R, Kowald L, et al. . Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica 2020;105:2150–63. PubMed PMC

Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther 2015;145:76–84. PubMed PMC

Xiang W, Yang CY, Bai L. MCL-1 inhibition in cancer treatment. Onco Targets Ther 2018;11:7301–14. PubMed PMC

Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, et al. . Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014;28:58–70. PubMed PMC

Fletcher S. MCL-1 inhibitors - where are we now (2019)? Expert Opin Ther Pat 2019;29:909–19. PubMed

Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. . Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 2013;27:1365–77. PubMed PMC

Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, et al. . Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 2013;27:1351–64. PubMed PMC

Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003;426:671–6. PubMed

Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, et al. . Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood 2018;132:1573–83. PubMed

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. . Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015;33:2848–56. PubMed PMC

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. . MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program. Blood 2013;121:4021–31. PubMed PMC

Sehn LH, Oestergaard MZ, Trněný M, Bosi A, Egyed M, Illes A, et al. . Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the phase III GOYA study. Hematol Oncol 2017;35:131–3.

Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. . MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis 2015;6:e1593. PubMed PMC

Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. . Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351–65. PubMed

Gutierrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, et al. . Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 1999;59:696–703. PubMed

Doucet JP, Hussain A, Al-Rasheed M, Gaidano G, Gutierrez MI, Magrath I, et al. . Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma 2004;45:357–62. PubMed

Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393–403. PubMed

Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. . Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053–8. PubMed

Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, Takaoka A, et al. . Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003;17:2233–8. PubMed PMC

Gomez-Bougie P, Menoret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem Biophys Res Commun 2011;413:460–4. PubMed

Haschka MD, Karbon G, Soratroi C, O'Neill KL, Luo X, Villunger A. MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment. Cell Death Differ 2020;27:2297–312. PubMed PMC

Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, et al. . NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci U S A 2018;115:12034–9. PubMed PMC

Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, et al. . Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia 2015;29:1702–12. PubMed PMC